Small molecules that increase the presynaptic function of aminergic cells may provide neuroprotection in Parkinson's disease (PD) as well as treatments for attention deficit hyperactivity disorder (ADHD) and depression. Model genetic organisms such as Drosophila melanogaster may enhance the detection of new drugs via modifier or 'enhancer/suppressor' screens, but this technique has not been applied to processes relevant to psychiatry. To identify new aminergic drugs in vivo, we used a mutation in the Drosophila vesicular monoamine transporter (dVMAT) as a sensitized genetic background and performed a suppressor screen. We fed dVMAT mutant larvae B1000 known drugs and quantitated rescue (suppression) of an amine-dependent locomotor deficit in the larva. To determine which drugs might specifically potentiate neurotransmitter release, we performed an additional secondary screen for drugs that require presynaptic amine storage to rescue larval locomotion. Using additional larval locomotion and adult fertility assays, we validated that at least one compound previously used clinically as an antineoplastic agent potentiates the presynaptic function of aminergic circuits. We suggest that structurally similar agents might be used to development treatments for PD, depression and ADHD, and that modifier screens in Drosophila provide a new strategy to screen for neuropsychiatric drugs. More generally, our findings demonstrate the power of physiologically based screens for identifying bioactive agents for select neurotransmitter systems.
INTRODUCTION
Most antidepressants and treatments of attention deficit hyperactivity disorder target the same proteins, mandating the development of novel screening strategies. Current treatments for Parkinson's disease (PD) are also limited and do not slow the underlying neurodegenerative process. The presynaptic proteins required for the exocytotic release of monoamines may serve as novel therapeutic targets for both of these illnesses. These include the release machinery itself, the vesicular monoamine transporter (VMAT), required for transport of all amines into synaptic vesicles, and other proteins that regulate these activities. 1 Multiple studies support the potential clinical relevance of these targets. VMAT regulates cytosolic concentrations of dopamine (DA), and the cytosolic pool of DA is neurotoxic. 2, 3 Loss of VMAT2 increases DA cell death, 4 whereas overexpression of VMAT is neuroprotective. 5, 6 Inhibition of VMAT causes a state resembling depression, 7, 8 and overexpression of VMAT mimics the effects of psychostimulants. 9 To date, drugs that increase the activity or expression of VMAT are not known. More generally, with the exception of the DA precursor L-3,4-dihydroxyphenylalanine, which increases DA storage via increased synthesis, current psychotropic drugs are not able to increase the exocytotic release of biogenic amines via other mechanisms. Amphetamines, by contrast, use alternative mechanisms to release biogenic amines, including efflux through the plasma membrane DA transporter, and may be neurotoxic. 10 'Enhancer/suppressor' or 'modifier' screens in Drosophila melanogaster are a powerful method to identify novel genes or drugs in biological pathways of interest. 11 To our knowledge, this strategy has not yet been used to identify drugs relevant to psychiatry, and relatively few screens have been reported for models of PD or other neurological diseases. Here we have used the Drosophila vesicular monoamine transporter (dVMAT) larval phenotype as a sensitized genetic background to screen for aminergic drugs and performed additional genetic tests to narrow potential mechanisms. We suggest that this strategy represents a new way to screen for psychotropic drugs in an intact organism without bias toward known drug targets and demonstrate its use to identify a possible new class of aminergic drugs. 25 1C on standard cornmeal molasses agar media in a 12 h light-dark cycle.
Drug exposure
Initial screens were performed using a library of 1039 drugs (10 mM stock) solubilized in dimethylsulfoxide (US Drug collection from Microsource Discovery Systems, Gaylordsville, CT, USA), and additional chemicals were used for validation assays as indicated (Sigma-Aldrich, St Louis, MO, USA). All drugs were added with vigorous mixing to molten cornmeal molasses agar media to a final concentration of p1% dimethylsulfoxide with food coloring (1% v/v, Kroger, Cincinnati, OH, USA) to confirm feeding. Larva homozygous for dVMAT P1 ( ± UAS-DVMAT, see text) were used for all assays and differentiated from dVMAT P1 /CyO siblings based on the observed rate of locomotion.
Larval locomotion assay
Two to three larvae were placed on the food/drug mixture for 30 s to acclimate and locomotion was scored as the number of 0.4 cm grids crossed over a 2 min period (time 0). After additional incubation on the drug/food mixture for 2 and 24 h (23 1C) assays were repeated.
Fertility assay
Three virgin females (0-3 day old) were mated with six CS males (0-3 days old) for three days on standard food then transferred to fresh food containing the indicated drug plus 1% food coloring (Kroger Foods, Cincinatti, OH, USA). Eggs laid over the ensuing 24 h period were counted.
RESULTS

Weak expression of 'leaky' DVMAT generates a functional hypomorph
Octopamine (OA) is required for the initiation and regulation of baseline motor behavior in Drosophila larva. 14 OA is thought to have a role in invertebrates similar to that of mammalian noradrenalin, but is synthesized via a different enzymatic pathway and contains one rather than two ring oxygens. 15 In addition to OA, dopaminergic circuits can influence locomotion under conditions of low OA and are responsible for the effects of several psychostimulants. 16 Locomotor rates of wt larvae are relatively high at baseline, making it difficult to detect the effects of exogenously applied amines ( Figure 1a ) or known aminergic drugs (data not shown). In contrast, dVMAT P1 null larvae show severely reduced baseline larval locomotion, 12 and dVMAT P1 larvae fed OA show a robust and easily quantified increase in baseline locomotion ( Figure 1b ). We reasoned that the dVMAT mutant might also be used as a sensitized genetic background to screen for novel aminergic drugs.
To allow the identification of drugs that might act presynaptically, we developed a sensitized background that retained some degree of presynaptic function. We crossed into the dVMAT P1 null background a leaky UAS-DVMAT transgene that expresses low levels of DVMAT in the absence of an additional exogenous Gal4 driver. 6 We designate this line (dVMAT P1 ; UAS-DVMAT) as the dVMAT 'weak expressor'. Locomotion rates of the 'weak expressor' are low relative to wt but significantly higher than the dVMAT null ( Figure 1c ). To confirm that the dVMAT weak expressor would respond to drugs that act presynaptically, we used amphetamine, which promotes the presynaptic release of monoamines in both mammals 10 and flies. 16 Amphetamine feeding caused a dosedependent increase in locomotion in the dVMAT weak expressor, but not the dVMAT null ( Figure 1d ).
Locomotion-based primary screen In our primary screen, (Figure 1e ) we tested whether any of 1039 drugs ( Supplementary Table S1 ) would increase locomotion in the dVMAT weak expressor, using two concentrations of each drug (10 and 100 mM). Locomotion was assayed before ingestion (0 h) and after 2 and 24 h of incubation on food containing each drug. A photo of an assay plate ( Figure 1f ) and a representative sample of data from the primary screen is shown (Figure 1g , Supplementary  Table S1 for names of all 1039 tested drugs and Supplementary Figure S1 for primary screen data). Averaging across all drugs and vehicle controls, the mean ± s.d. grid lines that traveled over 2 min at 0, 2 and 24 h was 1.18 ± 0.86, 1.33 ± 1.09 and 1.13 ± 1.2, respectively (n ¼ 2193). We identified 40 'strong hits' as drugs that increased locomotion at either 2 or 24 h and either 10 or 100 mM 43.5 s.d. (44.2 grid lines) above the mean at time 0 (Figures 2ad ). An additional 76 drugs were scored as 'weak hits': locomotion 42 but o3.5 s.d. above the mean (42.9 ando4.2 grid lines per 2 min, Supplementary Table S2 ).
Secondary screen
The drugs identified in our primary screen could act at several distinct sites in the locomotion circuit, but can be distinguished by their requirement for amine storage and release (Figure 2e ). Those acting presynaptically in aminergic cells or other upstream sites in the central nervous system (CNS) will require DVMAT to allow amine storage. These 'DVMAT dependent' drugs will stimulate movement in the dVMAT weak expressor but not the null. Conversely 'DVMAT independent' drugs that act post-synaptically at the aminergic synapse(s) that stimulate larval locomotion 14, 16 or downstream sites will not require DVMAT for amine storage and release, and will stimulate movement in both the DVMAT weak expressor and the null.
Of 40 strong hits from the primary screen, 15 were unable to stimulate movement in the dVMAT null mutant in the secondary screen ( Supplementary Table S3 ). These drugs were tentatively designated as DVMAT-dependent. In contrast, 11 drugs that strongly stimulated locomotion in the primary screen also strongly stimulated locomotion in the dVMAT null in the secondary screen and were tentatively designated as DVMAT independent ( Supplementary Table S3 ). A third group of 14 drugs weakly stimulated movement in the dVMAT null in the secondary screen, and thus did not clearly fall into either the DVMAT-dependent orindependent category ( Supplementary Table S3 ). To facilitate further analysis, we focused on those that were either DVMAT dependent or independent rather than these more ambiguous candidates.
Validation of candidates from primary and secondary screens
To validate the results of our primary and secondary screens, we obtained from commercial sources 13 of 15 DVMAT-dependent drugs ( Supplementary Table S4 lists other drugs that were not available). Six of these were validated to stimulate locomotion in the weak expressor ( Figure 3a Figure 3c ) paradoxically showed increased locomotion in the dVMAT null but not the weak expressor and were not pursued. Four of the drugs tentatively identified as DVMAT independent (and commercially available) were validated as able to stimulate locomotion in both the dVMAT null and the weak expressor ( Figure 3d ). In addition, two drugs tentatively identified as DVMAT dependent were reclassified as DVMAT independent, (Figure 3e ) bringing the total to six ( Table 1) . Retesting a subset of five weak hits from our primary screen ( Figure 3g ) identified only one additional DVMAT dependent drug for a total of seven ( Table 1) . As our yield was relatively low, we did not attempt to validate any additional 'weak' hits.
Several hits identified in our original screen could not be replicated during validation and, as noted above, three others were reclassified. There are several possible reasons why the results of our validation assays were not completely consistent with our initial screens. These include: (1) experimental error resulting from the manual collection of data by different individuals; (2) differences between the formulation, purity and degree of degradation between the drugs used in our initial screens which were from a commercial library, versus those used in the validation assays which were purchased from a separate source. Future screening efforts will employ an automated data collection system (not shown), reducing at least one potential source of varialbility.
Validated hits (Table 1) included several cholinergic compounds, consistent with the known role of acetylcholine in Drosophila locomotion and the cholinergic input to larval motoneurons 17, 18 (Figure 2e ). Others appeared to represent a range of drugs with varied known uses ( Table 1 ). The mode of action of these drugs in our assay may or may not be similar to the activity for which they are currently used. To address this issue and provide preliminary mechanistic information, we selected for further analysis one of the seven validated DVMAT-dependent drugs and one of the six DVMAT-independent drugs. We focused on drugs able to give a robust signal at the 2 h time point during the validation phase rather than those that only In our Primary Screen we assayed drugs for their ability to increase or 'rescue' the deficit in locomotion seen in larvae expressing low levels of DVMAT (the dVMAT 'Weak Expressor'). In the Secondary Screen, candidate drugs were tested for their ability to increase locomotion in the dVMAT null. Drugs able to rescue locomotion in both the Primary and Secondary screens were designated as 'DVMAT independent' , and therefore potentially acting via post-synaptic mechanisms. Conversely, drugs able to rescue locomotion in the Primary but not the Secondary screen were designated as 'DVMAT dependent' and potentially acting via presynaptic mechanisms to increase amine release. During the Validation Phase of the screen, candidates were retested and either confirmed as DVMAT dependent or independent, reclassified or discarded depending on the ability of a second formulation of drug to activate locomotion. (f ) A still photo from a videotape of two assay plates. The larva (arrowheads) on the top and bottom plates have moved B1 grid and 3-4 grids, respectively from the center of the plates. (g) Example of primary screen data. Drugs tested at both high (100 mM, designated 'H') and low (10 mM, designated 'L') concentrations at 0, 2 and 24 h as indicated. Dotted line: 4.2 grids per 2 min, used as cutoff for strong hits (for example, 2F6-H). stimulated locomotion after 24 h, as the former would be more likely to act via relatively direct mechanisms as opposed to longterm changes in transcription. Of the DVMAT-independent drugs, we focused on pergolide, a known amine receptor agonist in mammals (see below). Of the DVMAT-dependent drugs, we focused on dacarbazine, previously used only as an anticancer drug 19 rather than a psychotropic.
Further tests of pergolide and dacarbazine Additional dose response experiments show that both dacarbazine ( Figure 4a ) and pergolide ( Figure 4b ) increase locomotion at concentrations up to 0.5-1 mM in the weak expressor. To determine whether pergolide and dacarbazine were generally active as aminergic agents in the fly, we tested their affects on another amine-dependent behavior: egg-laying in the adult. This behavior is controlled predominantly by OA, 13, [20] [21] [22] [23] although oocyte development may be regulated in part by DA. 24 Consistent with its assignment as a DVMAT-independent drug in larval locomotion assays, pergolide at 1 mM partially rescued egg-laying in both the dVMAT null and weak expressors (Figure 4c ). By contrast, 1 mM dacarbazine rescued egg-laying in the dVMAT weak expressor but had no effect in the null mutant (Figure 4d ), thus demonstrating that it acts in a DVMAT-dependent fashion in at least two independent circuits in larvae and adults.
As the sensitized background used in our primary screen employs a 'leaky' UAS-DVMAT transgene that is expressed at low levels in the absence of a cell-specific Gal4 driver, it should allow low levels of amine storage and release from all types of aminergic neurons, including those that synthesize DA, 5HT and OA. However, as baseline larval locomotion and egg-laying are primarily regulated by OA, 13, 14, 20, 21 we focused further mechanistic experiments on OA circuits. We first tested the effects of the OA receptor antagonists mianserin and epinastine. 25, 26 (Both decrease the locomotion of CS larvae, Supplementary Figure S2 ). dVMAT null larvae were fed 1 mM pergolide for 2 h, followed by mianserin, epinastine or vehicle alone. Pergolide continued to stimulate locomotion after transfer to food containing vehicle alone (Figures 4e and f) . In contrast, although neither drug completely abolished the effect of pergolide, transfer to food containing mianserin or epinastine reduced the locomotor effects of pergolide by 60% (****Po0.0001 two-way analysis of variance (ANOVA); ***Po0.001, Bonferroni post test) and 33% (***Po0.0001, two-way ANOVA; *Po0.05, Bonferroni post test), respectively (Figures 4e and f, compare first black bars to second black bars). In support of the specificity of mianserin and epinastine for OA circuits, we tested these drugs on tyramine beta hydroxylase (TbH) mutants and found no effect (not shown). The simplest explanation of our results is that pergolide can act in part as an OA receptor agonist in Drosophila, in addition to its activity as a D2 receptor agonist in mammals, 27 and that activation of OA receptors by pergolide stimulates larval locomotion.
To determine whether OA synthesis is required for dacarbazine or pergolide to stimulate locomotion, we used the tyramine beta hydroxylase (TbH) mutant, which is unable to convert the precursor tyramine to OA. 13 Homozygous TbH mutants show defects in larval locomotor behavior consistent with a requirement for OA. 14, 28 Dacarbazine had no effect on locomotion behavior in the TbH null (Figure 4h ) as compared with the dVMAT weak expressor control. In contrast, pergolide (Figure 4i ) increased larval locomotion in both the TbH null and the dVMAT weak expressor. These results further suggest that dacarbazine may act within the OA cell itself to stimulate the amine storage and release, or at a site in the nervous system upstream of the OA cell that regulates baseline locomotion.
A structural analog of dacarbazine increases locomotion in the dVMAT weak expressor but not in the dVMAT null Dacarbazine is currently used as an antineoplastic agent. 29 Toxic effects would limit its use as a psychotropic in mammals, and high doses are toxic to fly larvae (Supplementary Figure S3 ). In mammals, dacarbazine is metabolized to methyldiazonium, which mediates DNA alkylation, plus the non-toxic 5-amino-4-imidazolecarboxamide (AICA) backbone 29 (Figure 4j ). Unlike dacarbazine, AICA does not show toxicity in the fly at high concentrations (Supplementary Figure S3 ). However, similar to dacarbazine, AICA increases locomotion in a dose-dependent fashion after either 2 h (Figure 4k ) or 4 h exposure (Supplementary Figure S4 ) in the dVMAT weak expressor but not the dVMAT null (Supplementary Figure S4 ). One available derivative of AICA is 5-aminoimidazole-4carboxamide 1-b-D-ribofuranoside (AICAR, Figure 4j ) a potential antihyperglycemic agent thought to act in part via stimulation of (f ) Betamethasone failed to stimulate locomotion and was discarded. (g) Retesting 'weak hits' . One drug (isopropamide) activated locomotion in the weak expressor (g, top) but not the null (g) and was classified as DVMAT dependent. Drugs were tested at two concentrations above the minimum that was effective in the primary and secondary screens: 10 mm, 100 mm and 1 mM or 100 mM, 1 mM and 10 mM as indicated. Dotted line: cutoff for validated hits (3 s.d. above the mean at time 0 for all drugs tested in the weak expressor during the validation phase (3.6 grid lines/ 2 min), or 4 s.d. above mean at time 0 for all drugs tested in the null during the validation phase (2.2 grid lines/2 min). Betameth., Betamethasone; Carbamaz., Carbamazepine; Chlorprom., Chlorpromazine; Dexameth., Dexamethasone.; Guaifen, Guaifenesin.
AMP kinase. 30 In contrast to AICA, AICAR did not increase locomotion in the dVMAT weak expressor at 2 or 4 h in either the weak expressor or the null (Figure 4l and Supplementary S4).
DISCUSSION
We describe here the use of a 'modifier' or 'enhancer/suppressor' screen for psychotropic drugs in Drosophila melanogaster. Screening for a change in functional output in an intact animal selects for targets that are physiologically relevant, and selects for drugs that are able penetrate a glial barrier to enter the CNS. 31 The use of a sensitized background (here the dVMAT mutant) focused our screen on a specific biological process (aminergic signaling) without limiting the range of protein targets. The sensitized genetic background also allowed the detection of pharmacological activities that are difficult to observe in the wt. We are not aware of any previous studies using this method to screen for aminergic drugs or any other small molecules relevant to the treatment of psychiatric illness. Importantly, we have identified drugs that give a desirable functional effect without selecting for a specific protein target. We recognize that additional experiments will be needed to determine the mechanism of action of any drugs identified in this manner. However, we emphasize that because of the unbiased nature of our screen, the potential mechanisms will not be restricted to known drug targets. We therefore propose that this approach will complement other existing methods of drug discovery in which specific protein targets are preselected, and may allow the detection of drugs that act on novel targets unrelated to those already used for the treatments for depression, attention deficit hyperactivity disorder and PD.
In preliminary transport experiments, we have not been able to detect a direct effect of dacarbazine on VMAT transport activity (data not shown). Indeed, we are not aware of any psychotropic drugs that can directly increase the physiological activity of a neurotransmitter transporter. Rather we suggest that the drugs we identify are more likely to increase VMAT activity in an indirect fashion. We suggest that the strength of our system and the use of As compared with animals treated with vehicle for 2 h followed by vehicle for an additional 2 h (VehXVeh), animals treated with 1 mM pergolide for 2 h followed by vehicle alone (PergXVeh) showed an increase in locomotion (For both panels e and f: two-way ANOVA, ***Po0.0001; Bonferroni post test, ***Po0.001, *Po0.05, n ¼ 6-12, error bars represent±s.e.m.). Larvae fed pergolide then mianserin (0.25 mg/ml, PergXMian) locomote less than larva fed pergolide followed by vehicle (PergXVeh). (f ) Larvae fed pergolide then epinastine (Perg ¼ 4Epi) locomote less than larva fed pergolide then vehicle (PergXVeh) but more than controls (VehXVeh and VehXepinastine), suggesting partial rather than complete inhibition of pergolide's effects by epinastine. (g, h) Dacarbazine but not pergolide requires presynaptic OA synthesis. an in situ aminergic circuit are that it will allow the detection of drugs that act on a variety of novel targets that act upstream of VMAT, or may otherwise increase amine release via other indirect mechanisms. We further suggest that such targets may not be present in less-complex screening platforms, and because they indirectly stimulate neurotransmission, may not be obvious 'aminergic' targets for drug development.
Although we used an octopaminergic circuit in our screen, some of the drugs we have identified may be generally active at other types of aminergic nerve terminals, similar to DVMAT and mammalian VMAT2, which are expressed broadly in most if not all aminergic neurons in the CNS. 1, 32 As the molecular mechanisms of monoamine release are conserved across many species, it is also possible that some drugs will be active in mammalian systems. Indeed, assays of peripheral blood in rodents and patients treated with dacarbazine demonstrate an increase in peripheral 5HT metabolites, due to release of 5HT from enterochromaffin cells. 33, 34 These observations support the notion that at least some of the drugs we have identified may be active across multiple types of aminergic neurons and have similar effects in mammals.
As dacarbazine is used as a chemotherapeutic to kill dividing cells, 29 it is unlikely to be directly useful as a psychotropic agent. We find that AICA, which lacks an alkylating moiety but is otherwise identical to dacarbazine, mimics its activity in the fly. Another derivative, AICAR, which is undergoing trials as an antihyperglycemic agent 30, 35 did not stimulate locomotion. It is likely that additional derivatives will need to be developed if this class of molecules is to be investigated for its potential effects in mammals.
In conclusion, our data support the use of modifier screens in the fly to identify novel aminergic agents. If any of the drugs we have identified or structurally related derivatives are found to increase amine release in mammals, they might be used to treat depression or attention deficit hyperactivity disorder. Increasing amine storage in vesicles also has the potential to sequester cytotoxic DA metabolites away from their site of action. 36 Thus, some identified drugs might provide novel neuroprotective strategies for PD. 5, 6, 37 In support of this possibility, preliminary data suggest that a subset of DVMAT-dependent drugs can increase the survival of mammalian dopaminergic neurons in culture (data not shown). More generally, we suggest that modifier screens in Drosophila provide a new way to screen for psychotropic drugs without bias toward previously identified protein targets. Similar screens also might be used to identify novel GABAergic (gamma-aminobutyric acid) or glutamatergic agents.
